A Pilot Study of KRX-0502 (Ferric Citrate, Administered Without Food, in Treating Iron-deficiency Anemia

Phase 2

Completed

• Conditions: Anemia of Chronic Kidney Disease
• Interventions: Drug: KRX-0502

• Registration Number: NCT02128074
• Lead Sponsor: Keryx Biopharmaceuticals

Brief Summary

The objective of the study is to evaluate the efficacy and safety of KRX-0502, administered without food, in treating iron deficiency anemia in subjects with stage 3 to 5 non-dialysis dependent chronic kidney disease (NDD-CKD).

Detailed Description

Previous clinical trials have tested KRX-0502 administered with food, in dialysis-dependent and NDD-CKD patients.

This clinical trial will evaluate the safety and efficacy of KRX-0502 in treating iron deficiency anemia in anemic, stage III to V NDD-CKD patients in a new dosing regimen (without food).

Study Timeline

• Study Start: 2014-04
• Study First Submitted: 2014-04-28
• Study First Submitted QC: 2014-04-29
• Study First Posted: 2014-05-01
• Primary Completion: 2014-11
• Study Completion: 2014-11
• Disposition First Submitted: 2017-04-27
• Disposition First Submitted QC: 2017-04-27
• Disposition First Posted: 2017-05-01
• Status Verified: 2017-11
• Results First Submitted: 2017-11-30
• Results First Submitted QC: 2017-11-30
• Last Update Submitted: 2017-11-30
• Results First Posted: 2018-08-24
• Last Update Posted: 2018-08-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• Males and non-lactating females with negative serum pregnancy test (for females of child-bearing potential) at Screening
• Age ≥ 18 years
• Serum ferritin ≤ 300 ng/mL and TSAT ≤ 25% at Screening
• Hemoglobin ≥9.0 g/dL and ≤11.5 g/dL at Screening
• eGFR <60 mL/min at Screening using the 4-variable Modification of Diet in Renal Disease (MDRD) equation

Exclusion Criteria

• Subjects receiving phosphate binder medication(s) at, or within 4 weeks prior to, screening
• Symptomatic gastrointestinal bleeding, inflammatory bowel disease, inflammatory bowel syndrome and/or Crohn's Disease within 24 weeks prior to \ Screening
• Evidence of acute kidney injury or requirement for dialysis within 8 weeks prior to Screening
• Kidney transplant anticipated or start of dialysis expected within 16 weeks of Screening
• History of hemochromatosis
• IV iron administered within 4 weeks prior to Screening
• Erythropoiesis-Stimulating Agent (ESA) administered within 4 weeks prior to Screening
• Blood transfusion within 4 weeks prior to Screening
• Receipt of any investigational drug within 4 weeks prior to Screening
• Cause of anemia other than iron deficiency or chronic kidney disease
• History of malignancy in the last five years
• Active drug or alcohol dependence or abuse (excluding tobacco use) within the 12 months prior to Screening
• Any known allergies to iron products
• Previous intolerance to oral ferric citrate
• Psychiatric disorder that interferes with the subject's ability to comply with the study protocol
• Planned surgery or hospitalization during the trial
• Any other medical condition that, in the opinion of the PI, renders the subject unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the subject

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
KRX-0502	KRX-0502	KRX-0502 (ferric citrate)

Primary Outcome Measures

Name	Time	Method
Change in Hemoglobin From Baseline to the End of 8-week Treatment Period	8 weeks

Trial Locations

Locations (3)

Western Galilee Hospital; 🇮🇱 Nahariya, Israel

Barzilai Medical Center; 🇮🇱 Ashkelon, Israel

Nazareth Hospital- EMMS; 🇮🇱 Nazareth, Israel